UBS Warburg Upgrades Bard to 'Buy'

Analyst David Lothson says Tyco's problems has driven down the value of the medical device maker

UBS Warburg upgraded C R Bard (BCR ) to buy from hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.